Maurie Markman, MD
The importance of randomized trials in oncology in the development of solid evidence-based care is well recognized. Data from such studies presented at major oncology meetings and published in high-impact medical journals can be practice changing. Randomized trials may reveal superior efficacy, such as improved progression-free or overall survival, or the study end point may involve noninferior outcomes with reduced clinically relevant toxicities. Of course, it is always hoped that practice-changing trial data will reveal improvement both in efficacy and in treatment-associated adverse effects.
... to read the full story